Skip to main content Skip to navigation
CD13 PE-Cy™7
Product Details
Down Arrow Up Arrow


BD™
ANPEP; APN; Aminopeptidase N; Alanyl aminopeptidase; LAP1; PEPN
Human
Mouse BALB/c X C57BL/6 IgG1, κ
KG-1a Cell Line
Flow cytometry
25 μg/mL
5 μL
V MA21
290
Phosphate buffered saline with gelatin and 0.1% sodium azide.
ASR


Preparation And Storage

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

338432 Rev. 1
Antibody Details
Down Arrow Up Arrow
L138

The CD13 antibody, clone L138 (also known as Leu-M7), is derived from the hybridization of Sp2/0 mouse myeloma cells with spleen cells isolated from BALB/c × C57BL/6 hybrid mice immunized with the KG-1a cell line.

The CD13 antibody specifically binds to a glycosylated 150-kilodalton (kDa) type II integral membrane zinc-metalloprotease. The CD13 antigen is also known as aminopeptidase N, APN, ANPEP, and gp150.

338432 Rev. 1
Format Details
Down Arrow Up Arrow
PE-Cy7
PE-Cy7 dye is a part of the BD PE family of dyes. This tandem fluorochrome is comprised of a R-Phycoerythrin (PE) donor that has excitation maxima (Ex Max) of 496-nm and 566-nm and an acceptor dye, Cy™7, with an emission maximum (Em Max) at 781-nm. PE can be excited by the Blue (488-nm), Green (532-nm) and yellow-green (561-nm) lasers and detected using an optical filter centered near 781 nm (e.g., a 760/60-nm bandpass filter). The donor dye can be excited by the Blue (488-nm), Green (532-nm) and yellow-green (561-nm) lasers and the acceptor dye can be excited by the Red (627–640-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
PE-Cy7
Yellow-Green 488 nm, 532 nm, 561 nm
496 nm, 566 nm
781 nm
338432 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "338432" on CiteAb

Development References (9)

  1. Ashmun RA, Holmes KV, Shapiro LH, et al. CD13 (aminopeptidase N) cluster workshop report. In: Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995::771-775.
  2. Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Musgrove E. Myeloid progenitor surface antigen identified by monoclonal antibody.. Br J Haematol. 1985; 61(1):11-20. (Biology). View Reference
  3. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
  4. Clinical and Laboratory Standards Institute. 2005. (Biology).
  5. Howard MR, Thomas L, Reid MM. Variable detection of myeloid antigens in childhood acute lymphoblastic leukaemia.. J Clin Pathol. 1994; 47(11):1006-9. (Biology). View Reference
  6. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13).. Blood. 1999; 94(7):2333-42. (Biology). View Reference
  7. Mina-Osorio P, Winnicka B, O'Conor C, et al. CD13 is a novel mediator of monocytic/endothelial cell adhesion.. J Leukoc Biol. 2008; 84(2):448-59. (Biology). View Reference
  8. Yeager CL, Ashmun RA, Williams RK, et al. Human aminopeptidase N is a receptor for human coronavirus 229E.. Nature. 1992; 357(6377):420-2. (Biology). View Reference
  9. Zola H, Swart B, Nicholson I, Voss E. Leukocyte and Stromal Cell Molecules: The CD Markers. 2007. (Biology).
View All (9) View Less
338432 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.